VivoSeq
Infectious Disease

Pneumococcal Meningitis

2

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

Pneumococcal Meningitis is an early-stage landscape with 2 programs across 1 company. The most active players are Viatris Specialty LLC. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

50/100

Attrition Rate

50/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Viatris Specialty LLC

1 program

Approved

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

Daptomycin

Baxter Healthcare Corporation

Phase 3
No programs
Approved1

Phenytoin

Viatris Specialty LLC

Analysis

Trial Status

2

clinical trials

Completed1 · 50%
Terminated1 · 50%

Clinical Trials

Trial Activity

Adjunction of Daptomycin for the Treatment of Pneumococcal Meningitis
Completed·—·Phase 2·NCT03480191·112 enrolled
Study on the Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old.
Terminated·MM. Carmen Cabellos Minguez·Phase 4·NCT01478035·26 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)